亚太药业(002370) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥68,322,640.18, a decrease of 13.51% compared to ¥78,994,810.92 in the same period last year[3] - The net profit attributable to shareholders was -¥28,871,344.89, representing a decline of 20.59% from -¥23,941,299.97 year-on-year[3] - Total operating revenue decreased to ¥68,322,640.18 from ¥78,994,810.92, a decline of approximately 13.3% year-over-year[23] - Net loss for the period was ¥28,871,344.89, compared to a net loss of ¥23,941,299.97 in the previous period, indicating a worsening of approximately 20.5%[24] Cash Flow - The net cash flow from operating activities was -¥9,488,898.62, a significant drop of 1,420.49% compared to -¥624,068.40 in the previous year[3] - Cash flow from operating activities showed a net outflow of ¥9,488,898.62, compared to a smaller outflow of ¥624,068.40 in the previous period[26] - The net increase in cash and cash equivalents was -¥22,421,422.02, with an ending balance of ¥778,696,857.36[28] - The beginning balance of cash and cash equivalents was ¥801,118,279.38, indicating a decrease in cash reserves[28] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,561,545,911.60, down 3.06% from ¥1,610,781,365.72 at the end of the previous year[3] - Total liabilities decreased to ¥1,156,637,472.51 from ¥1,177,819,792.64, a reduction of about 1.8%[21] - Current assets decreased from RMB 995,848,724.97 to RMB 962,754,755.53, with cash and cash equivalents at RMB 798,691,768.56[19][20] - The company’s non-current assets totaled RMB 598,791,156.07, down from RMB 614,932,640.75[20] Shareholder Equity - The equity attributable to shareholders decreased by 6.48% to ¥404,908,439.09 from ¥432,961,573.08 at the end of the previous year[3] - Total equity attributable to shareholders decreased to ¥404,908,439.09 from ¥432,961,573.08, a decline of approximately 6.5%[21] Expenses - Research and development expenses were ¥3,772,402.86, a reduction of 50.31% compared to ¥7,591,502.47 in the same period last year[7] - The company reported a significant decrease in sales expenses, which were ¥20,771,110.81, down 37.01% from ¥32,974,076.93 year-on-year[7] - The company incurred financial expenses of ¥10,862,396.97, slightly down from ¥11,870,398.59, a reduction of about 8.5%[23] Legal Matters - The company received a lawsuit notification regarding a securities false statement liability dispute with a total claim amount of RMB 286,900[12] - The company is pursuing legal action for a performance compensation of RMB 256,380,400 due to unfulfilled commitments from a previous acquisition[17] Shareholder Changes - After a recent equity change, the largest shareholder, Ningbo Fubon Holdings Group, now holds 18.02% of the total shares, while Zhejiang Yatai Group holds 2.72%[13][14] - The company completed a share transfer agreement at a price of RMB 5.21 per share, totaling RMB 203,190,000 for 39 million shares, increasing Fubon Group's stake significantly[14] Management Changes - The company is undergoing a change in control, with the management team now comprising four individuals instead of a single controlling shareholder[16]